Last Updated: October 1, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Spain: These 60 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Generic Entry Dates in Other Countries

African Regional IP Organization (ARIPO) Argentina Australia Austria Brazil Canada Chile China Colombia Costa Rica Croatia Cuba Cyprus Denmark Dominican Republic Ecuador Eurasian Patent Organization European Patent Office Finland France Georgia, Republic of Germany Guatemala Honduras Hong Kong Hungary Israel Italy Japan Jordan Lithuania Luxembourg Malaysia Mexico Montenegro Morocco Netherlands New Zealand Nicaragua Norway Panama Peru Philippines Poland Portugal Russian Federation San Marino Saudi Arabia Serbia Singapore Slovenia South Africa South Korea Taiwan Tunisia Turkey Ukraine United Kingdom United States Uruguay
Preferred citation:
Friedman, Yali, "Spain: These 60 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can TYMLOS (abaloparatide) generic drug versions launch in Spain?

Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: Spain Patent 2,637,283

Drug Price Trends for TYMLOS
TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. Additional details are available on the abaloparatide profile page.

When can TYMLOS (abaloparatide) generic drug versions launch in Spain?

Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: Spain Patent 2,739,459

Drug Price Trends for TYMLOS
TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. Additional details are available on the abaloparatide profile page.

When can COTELLIC (cobimetinib fumarate) generic drug versions launch in Spain?

Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: Spain Patent 2,365,070

COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.

See drug price trends for COTELLIC.

The generic ingredient in COTELLIC is cobimetinib fumarate. Additional details are available on the cobimetinib fumarate profile page.

When can LYRICA CR (pregabalin) generic drug versions launch in Spain?

Generic name: pregabalin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 23, 2026
Generic Entry Controlled by: Spain Patent 2,449,231

Drug Price Trends for LYRICA CR
LYRICA CR is a drug marketed by Upjohn. There are three patents protecting this drug and four Paragraph IV challenges. Six tentatively approved generics are ready to enter the market.

See drug price trends for LYRICA CR.

The generic ingredient in LYRICA CR is pregabalin. Additional details are available on the pregabalin profile page.

When can INREBIC (fedratinib hydrochloride) generic drug versions launch in Spain?

Generic name: fedratinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 26, 2026
Generic Entry Controlled by: Spain Patent 2,595,636

INREBIC is a drug marketed by Bristol-myers. There are five patents protecting this drug. There has been litigation on patents covering INREBIC

See drug price trends for INREBIC.

The generic ingredient in INREBIC is fedratinib hydrochloride. Additional details are available on the fedratinib hydrochloride profile page.

When can BEVYXXA (betrixaban) generic drug versions launch in Spain?

Generic name: betrixaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2026
Generic Entry Controlled by: Spain Patent 2,384,116

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in Spain?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Spain Patent 2,547,481

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in Spain?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Spain Patent 2,684,322

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in Spain?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Spain Patent 2,847,275

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in Spain?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Spain Patent 2,926,912

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in Spain?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Spain Patent 2,547,481

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in Spain?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Spain Patent 2,684,322

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in Spain?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Spain Patent 2,847,275

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in Spain?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Spain Patent 2,926,912

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can KORSUVA (difelikefalin acetate) generic drug versions launch in Spain?

Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: Spain Patent 2,394,377

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. Additional details are available on the difelikefalin acetate profile page.

When can ZTALMY (ganaxolone) generic drug versions launch in Spain?

Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Spain Patent 2,812,250

ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.

When can ZUBSOLV (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch in Spain?

Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Spain Patent 2,439,581

Drug Price Trends for ZUBSOLV
ZUBSOLV is a drug marketed by Edenbridge Pharms. There are ten patents protecting this drug and four Paragraph IV challenges. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering ZUBSOLV

See drug price trends for ZUBSOLV.

The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Spain?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Spain Patent 2,387,923

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Spain?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Spain Patent 2,524,009

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can LETAIRIS (ambrisentan) generic drug versions launch in Spain?

Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Spain Patent 2,544,724

LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LETAIRIS

See drug price trends for LETAIRIS.

The generic ingredient in LETAIRIS is ambrisentan. Additional details are available on the ambrisentan profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Spain?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Spain Patent 2,625,083

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in Spain?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Spain Patent 2,461,315

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can VYKAT XR (diazoxide choline) generic drug versions launch in Spain?

Generic name: diazoxide choline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: Spain Patent 2,374,963

VYKAT XR is a drug marketed by Soleno Therap. There are six patents protecting this drug.

The generic ingredient in VYKAT XR is diazoxide choline. Additional details are available on the diazoxide choline profile page.

When can VYKAT XR (diazoxide choline) generic drug versions launch in Spain?

Generic name: diazoxide choline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: Spain Patent 2,984,297

VYKAT XR is a drug marketed by Soleno Therap. There are six patents protecting this drug.

The generic ingredient in VYKAT XR is diazoxide choline. Additional details are available on the diazoxide choline profile page.

When can SEYSARA (sarecycline hydrochloride) generic drug versions launch in Spain?

Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2026
Generic Entry Controlled by: Spain Patent 2,701,725

SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.

See drug price trends for SEYSARA.

The generic ingredient in SEYSARA is sarecycline hydrochloride. Additional details are available on the sarecycline hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Spain?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Spain Patent 2,403,206

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Spain?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Spain Patent 2,761,180

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in Spain?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Spain Patent 2,763,829

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can NESINA (alogliptin benzoate) generic drug versions launch in Spain?

Generic name: alogliptin benzoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Spain Patent 2,639,854

Drug Price Trends for NESINA
NESINA is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering NESINA

See drug price trends for NESINA.

The generic ingredient in NESINA is alogliptin benzoate. Additional details are available on the alogliptin benzoate profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Spain?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Spain Patent 2,354,397

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Spain?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Spain Patent 2,560,527

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Spain?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Spain Patent 2,674,681

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Spain?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Spain Patent 2,560,527

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Spain?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Spain Patent 2,674,681

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can VANFLYTA (quizartinib dihydrochloride) generic drug versions launch in Spain?

Generic name: quizartinib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2027
Generic Entry Controlled by: Spain Patent 2,422,890

VANFLYTA is a drug marketed by Daiichi Sankyo Inc. There are eleven patents protecting this drug.

See drug price trends for VANFLYTA.

The generic ingredient in VANFLYTA is quizartinib dihydrochloride. Additional details are available on the quizartinib dihydrochloride profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Spain?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Spain Patent 2,375,503

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Spain?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Spain Patent 2,620,459

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch in Spain?

Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Spain Patent 2,743,784

Drug Price Trends for EDARBI
EDARBI is a drug marketed by Azurity. There is one patent protecting this drug. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. Additional details are available on the azilsartan kamedoxomil profile page.

When can BYSANTI (milsaperidone) generic drug versions launch in Spain?

Generic name: milsaperidone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 29, 2027
Generic Entry Controlled by: Spain Patent 2,542,967

BYSANTI is a drug marketed by Vanda Pharms Inc. There are ten patents protecting this drug. There has been litigation on patents covering BYSANTI

The generic ingredient in BYSANTI is milsaperidone. Additional details are available on the milsaperidone profile page.

When can INLYTA (axitinib) generic drug versions launch in Spain?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Spain Patent 2,634,866

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can INLYTA (axitinib) generic drug versions launch in Spain?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Spain Patent 2,919,351

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Spain?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Spain Patent 2,554,353

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Spain?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Spain Patent 2,580,803

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Spain?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Spain Patent 2,659,364

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Spain?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Spain Patent 2,882,684

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch in Spain?

Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: Spain Patent 2,404,818

Drug Price Trends for QVAR REDIHALER
QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. Additional details are available on the beclomethasone dipropionate profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Spain?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Spain Patent 2,565,179

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Spain?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Spain Patent 2,981,985

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Spain?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Spain Patent 3,032,244

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Spain?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Spain Patent 3,073,615

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Spain?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: Spain Patent 2,555,515

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Spain?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Spain Patent 2,628,025

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can CONTRAVE (bupropion hydrochloride; naltrexone hydrochloride) generic drug versions launch in Spain?

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 31, 2027
Generic Entry Controlled by: Spain Patent 2,749,800

CONTRAVE is a drug marketed by Azurity. There are eighteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Spain?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Spain Patent 2,611,020

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Spain?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Spain Patent 2,611,020

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Spain?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Spain Patent 2,467,665

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Spain?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Spain Patent 2,575,797

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Spain?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Spain Patent 2,714,092

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Spain?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Spain Patent 2,903,444

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch in Spain?

Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 15, 2027
Generic Entry Controlled by: Spain Patent 2,379,200

Drug Price Trends for TRINTELLIX
TRINTELLIX is a drug marketed by Takeda Pharms Usa. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering TRINTELLIX

See drug price trends for TRINTELLIX.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. Additional details are available on the vortioxetine hydrobromide profile page.

When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch in Spain?

Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 15, 2027
Generic Entry Controlled by: Spain Patent 2,432,102

Drug Price Trends for TRINTELLIX
TRINTELLIX is a drug marketed by Takeda Pharms Usa. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering TRINTELLIX

See drug price trends for TRINTELLIX.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. Additional details are available on the vortioxetine hydrobromide profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in Spain?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Spain Patent 2,550,504

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in Spain?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Spain Patent 2,352,360

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch in Spain?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Spain Patent 2,423,951

Drug Price Trends for EPIDUO
EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch in Spain?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Spain Patent 2,423,951

Drug Price Trends for EPIDUO FORTE
EPIDUO FORTE is a drug marketed by Galderma Labs. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Spain?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Spain Patent 2,526,352

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Spain?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Spain Patent 2,614,283

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in Spain?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: Spain Patent 2,603,879

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can TRIFERIC (ferric pyrophosphate citrate) generic drug versions launch in Spain?

Generic name: ferric pyrophosphate citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Spain Patent 2,383,713

TRIFERIC is a drug marketed by Rockwell Medical Inc. There are two patents protecting this drug.

See drug price trends for TRIFERIC.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. Additional details are available on the ferric pyrophosphate citrate profile page.

When can TRIFERIC AVNU (ferric pyrophosphate citrate) generic drug versions launch in Spain?

Generic name: ferric pyrophosphate citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Spain Patent 2,383,713

TRIFERIC AVNU is a drug marketed by Rockwell Medical Inc. There is one patent protecting this drug.

See drug price trends for TRIFERIC AVNU.

The generic ingredient in TRIFERIC AVNU is ferric pyrophosphate citrate. Additional details are available on the ferric pyrophosphate citrate profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Spain?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Spain Patent 2,462,946

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Spain?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Spain Patent 2,551,910

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Spain?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Spain Patent 2,554,934

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Spain?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Spain Patent 2,732,326

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in Spain?

Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 09, 2027
Generic Entry Controlled by: Spain Patent 2,662,590

Drug Price Trends for DAKLINZA
DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. Additional details are available on the daclatasvir dihydrochloride profile page.

When can INTRAROSA (prasterone) generic drug versions launch in Spain?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Spain Patent 2,888,104

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in Spain?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: Spain Patent 2,768,224

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in Spain?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: Spain Patent 3,030,116

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can BRILINTA (ticagrelor) generic drug versions launch in Spain?

Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 20, 2027
Generic Entry Controlled by: Spain Patent 2,625,930

Drug Price Trends for BRILINTA
BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in Spain?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: Spain Patent 2,659,716

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can MYRBETRIQ (mirabegron) generic drug versions launch in Spain?

Generic name: mirabegron
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 02, 2027
Generic Entry Controlled by: Spain Patent 2,393,525

MYRBETRIQ is a drug marketed by Apgdi. There are six patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering MYRBETRIQ

See drug price trends for MYRBETRIQ.

The generic ingredient in MYRBETRIQ is mirabegron. Additional details are available on the mirabegron profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Spain?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Spain Patent 2,703,158

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Spain?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Spain Patent 2,908,719

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Spain?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Spain Patent 2,950,337

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Spain?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Spain Patent 2,951,457

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Spain?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Spain Patent 2,559,528

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in Spain?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Spain Patent 2,613,936

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Spain?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Spain Patent 2,513,390

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Spain?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Spain Patent 2,513,390

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

Last updated: May 12, 2026

Spain Branded vs Generic Drug Markets Assessment and Regulatory Opportunities and Challenges

Spain is one of Europe’s most active markets for both branded and generic medicines, with near-term regulatory leverage driven by the national reference pricing system, prescribing and substitution rules, parallel import pressure, and ongoing cost-containment reforms at the regional and national levels. The generic segment has expanded through price competition, but brand holders still retain defensible niches where patent/market exclusivity, lifecycle IP (formulations, methods, dosing), and payer contracting strategies slow erosion. For companies considering entry or investment, the key constraints are Spain’s price-setting and reimbursement processes, administrative data linkages that delay launches, and a litigation-heavy environment where originators increasingly enforce second-wave patents and data exclusivity.

What are the current dynamics in Spain’s branded vs generic drug markets?

Featured answer: Spain’s generic share is high versus branded, and growth is sustained by price and reimbursement mechanisms that steer volume toward lower-cost products, with payer controls implemented through regional formularies and contracting.

Market structure: how volume and spend shift

  • Volume: Generics capture a large share of prescriptions in off-patent molecules due to substitution incentives and competitive pricing.
  • Spend: Even when volume shifts, total spend depends on therapeutic category mix, uptake speed, and price cuts driven by reference pricing and tenders.
  • Regional execution: Coverage decisions and tendering practices vary across Spain’s autonomous communities, shaping net pricing and launch timing.

Competitive implications by molecule lifecycle stage

  • Pre-expiry (brand protected): Brands can sustain pricing longer through managed-entry-style contracting and formulary positioning.
  • Post-expiry (generic ramp): Early entrants tend to gain volume if pricing clears quickly and substitution is operationally smooth.
  • Lifecycle IP (brand defense): Brands use formulation or method-of-use patents to delay generic substitution and reimbursement for specific presentations or indications.

How does Spain regulate drug pricing and reimbursement for branded and generics?

Featured answer: Reimbursement and price-setting are the central gatekeepers. Generics face automatic downward pressure through reference pricing and competition, while brands face renegotiation pressure when alternatives emerge.

Core pricing and reimbursement mechanics

  • Reference pricing: Sets maximum reimbursable price for interchangeables in a given therapeutic “reference” grouping. When generics enter, brands typically face downward pressure or reduced reimbursed share.
  • Tendering and contracting: National and regional purchasing mechanisms can drive additional price concessions beyond reference pricing, especially in hospital segments.
  • Health technology assessment and budget impact: New branded launches and expansions are assessed for added value; payers push for pricing that aligns with clinical benefit and budget impact.

Net price outcomes: typical direction of travel

  • Generics: Higher likelihood of faster net price reductions following entry as the reimbursement cap resets to the reference benchmark.
  • Brands: Greater risk of “value erosion” after genericization as reimbursed prices are pressured and formularies adjust.

What is the substitution and dispensing framework for generics in Spain?

Featured answer: Substitution is permitted and often incentivized through reimbursement and dispensing rules; operational differences between retail and hospital workflows affect real-world substitution speed.

Key execution layers

  • Prescriber behavior: “No substitution” style constraints can reduce substitution, but payer and pharmacist processes often still favor lower-cost alternatives.
  • Pharmacy dispensing: Pharmacists can substitute where rules permit and where the reimbursed product list supports it.
  • Interchangeability: Substitution depends on whether the generic is considered therapeutically equivalent and on matching strengths/formats.

Practical launch barriers for generic entrants

  • Presentation-specific coverage: If only certain strengths or pharmaceutical forms are interchangeably recognized, launch impact can be uneven.
  • Administrative system readiness: Data registration, product listing, and warehouse supply must align with reimbursement clearance to avoid lost market windows.

How strong are Spain’s patent and data exclusivity protections for originators?

Featured answer: Patent enforcement and data exclusivity interact with reimbursement and substitution rules. Originators can use secondary IP to defend specific indications, presentations, and manufacturing processes.

Patent estate enforcement pattern

  • Primary patents: Determine earliest generic entry opportunities.
  • Secondary patents: Commonly target:
    • new formulations (extended-release, fixed combinations)
    • dosing regimens and titration
    • manufacturing/process improvements
    • indication-specific method-of-use claims

Data and regulatory exclusivity levers

  • Data exclusivity and market exclusivity: Affect the ability of follow-on applicants to rely on originator dossiers and can delay approval even if patent status is contested.
  • Orphan, pediatric, and additional protection mechanisms: Can extend effective exclusivity in selected cases, depending on eligibility.

When do originator brands lose exclusivity in Spain?

Featured answer: Generic and biosimilar timing in Spain is governed by the intersection of patent expiration dates, any supplementary protection mechanisms, and regulatory exclusivity periods. Once generic entry is administratively enabled, reference pricing and substitution accelerate erosion.

Launch timing checklist used in market modeling

  1. Regulatory exclusivity end: Impacts approval pathway feasibility.
  2. Patent expiration: Defines legal entry window for competing products.
  3. Appeal and litigation stay effects: Can delay market access even after technical approval.
  4. Reimbursement and pricing clearance: Determines the effective commercial launch date.
  5. Tender cycles: For hospital products, the next procurement round can shift uptake by months.

What patents typically protect branded medicines against generics in Spain?

Featured answer: The most common IP barriers are formulation, dosing, and method-of-use patents that map to the exact presentation or indication that generics would need to mirror to obtain substitution and reimbursement acceptance.

Lifecycle IP clusters to screen

  • Oral solid dosage reformulations
  • Extended-release or controlled-release technologies
  • Fixed-dose combinations
  • Patient subpopulation or indication-specific claims
  • Manufacturing and particle engineering/process patents
  • Device-adjacent claims (when combination products are implicated)

Litigation posture and enforcement targets

  • Injunction and interim relief: Used to block market launch or limit supply.
  • Scope of infringement: Brands often argue “non-interchangeability” at the product presentation level, not only active ingredient.
  • Settlement agreements: Commonly structure generic entry timing or market allocation for first-to-file products.

How do Paragraph IV-style challenges work in Spain?

Featured answer: Spain’s generic challenge framework is primarily driven by patent linkage and national/European enforcement rather than the US “Paragraph IV” label. In practice, challenges target validity or non-infringement and are litigated to influence market entry.

Practical equivalent in Spain strategy

  • Generics attempt to launch at the first legally permitted date for their chosen dossier reliance and IP position.
  • Originators seek injunctions and negotiate settlements when risk or uncertainty is high.

Outcome effect

  • Even if a generic gains approval, infringement rulings or interim orders can delay reimbursement recognition and commercial availability.

What is the Orange Book status in Spain, and where do companies get exclusivity information?

Featured answer: Spain does not use the US Orange Book. Market exclusivity and patent information are sourced from Spanish patent and regulatory status databases, product dossiers, and national lists used in reimbursement/payer decisions.

Where exclusivity information is operationally surfaced

  • Regulatory approval records
  • National listings used for reimbursement and reference pricing
  • Court and administrative decisions affecting enforceability

(A direct Orange Book mapping is not available in Spain because the system is structured differently across jurisdictions.)

What generic entry risks exist for Spain launches?

Featured answer: The dominant risks are administrative delays in reimbursement listing, injunction/litigation outcomes that block supply, and price erosion dynamics that can make the launch unprofitable even after clearance.

Commercial and operational risk map

  • Legal risk: Injunction or non-infringement outcome, plus settlement terms that shift launch timing.
  • Regulatory risk: Exclusivity blocks or dossier reliance restrictions.
  • Pricing risk: Reference pricing reset timing and tender-driven cuts.
  • Execution risk: Lack of supply readiness aligned to reimbursement approval windows.
  • Market access risk: Formularies and regional contracting delay uptake.

First-to-market vs follower

  • First generic: Higher chance of capturing volume early if reimbursement clears.
  • Follower generics: Face faster price declines; depend on lower COGS and tender participation readiness.

What biosimilar opportunities and challenges exist in Spain?

Featured answer: Spain offers meaningful biosimilar opportunity where patent and data exclusivity barriers clear, but competitive uptake depends on tender rules, hospital formulary acceptance, and originator switching policies.

Biosimilar value drivers

  • Hospital procurement: Tend to create near-term volume when biosimilars are positioned on formularies.
  • Switching: Uptake accelerates when clinical governance allows automatic substitution and when pharmacists support switching protocols.
  • Multiple-supplier dynamics: With higher competition, net prices trend down faster.

Biosimilar risks

  • Patent estates: Often more complex for biologics (device, formulation, process, and manufacturing-specific claims).
  • Reference product switching friction: Clinical committees can delay adoption even after legal clearance.
  • Tender cycle gating: Even if a biosimilar is authorized, participation may require next procurement round.

How does Spain’s regulatory environment compare with Germany, France, and the UK for brands and generics?

Featured answer: Spain is comparatively stringent on budget impact and net price outcomes through reference pricing and regional contracting. Its clinical and administrative execution can be slower than the UK’s centralized cadence, while patent enforcement dynamics are similar to other EU markets.

Competitive impact by geography

  • Germany: Strong reference pricing and bargaining discipline; tender influence is material.
  • France: Higher focus on HTA and negotiated prices; biosimilar switch policy is structured differently.
  • UK: Centralized systems change the pace of launch and reimbursement decisions.
  • Spain: Regional autonomy and tender execution create uneven uptake timing across communities.

Which therapeutic categories show the strongest branded pricing defense vs generic substitution in Spain?

Featured answer: Categories with complex care pathways, hospital-only administration, and entrenched formulary preferences tend to retain branded advantage longer, while low-complexity oral generics see faster substitution.

Pattern recognition for category risk scoring

  • Branded defense tends to be stronger in:
    • specialty medicines with hospital-only or infusion-controlled settings
    • drugs with complex dosing regimens or patient monitoring
    • products with meaningful lifecycle IP or indication-specific patents
  • Generic substitution tends to be faster in:
    • common oral small molecules with clear interchangeability
    • established reference pricing groupings
    • therapies with broad outpatient prescribing behavior

How do hospital tenders and regional formularies affect the commercial success of generics?

Featured answer: Hospital tenders and regional formularies can determine whether generics achieve meaningful volume and pricing even after legal and technical readiness.

What to model in market entry plans

  • Tender frequency: Timing drives the gap between approval and real volume.
  • Contract structure: Exclusive or quasi-exclusive awards can limit immediate competition.
  • Clinical committee preferences: Biosimilar and brand-switch decisions can be committee-driven.
  • Regional product lists: Administrative inclusion can delay or accelerate adoption.

What patent litigation affects Spain generic entry most often?

Featured answer: Litigation affects launch through injunctions, interim relief, and settlement structures that define effective entry dates and product scope.

Common litigation pathways

  • Injunction requests: Can block supply pending outcome.
  • Validity challenges: Aim to invalidate the key claims.
  • Non-infringement arguments: Often product-presentation-specific in lifecycle cases.
  • Settlement agreements: Typical outcome is delayed entry or narrow carve-outs.

Settlement economics

  • Settlement terms often trade off:
    • earlier generic revenue potential vs risk of injunction
    • legal fees and uncertainty
    • post-settlement pricing constraints due to reference pricing

What are the regulatory opportunities for new entrants in Spain?

Featured answer: The best opportunities cluster where exclusivity gaps are reachable in the near term, where regional tenders support rapid adoption, and where the entrant’s product matches substitution and reimbursement requirements in presentation and strength.

Opportunity zones

  • Near-expiry small molecules with clean interchangeability profiles
  • Biosimilars when patent estates and switching policies are favorable
  • Lifecycle gaps where originator second-wave patents do not cover all presentations or patient subgroups
  • Manufacturing differentiation that reduces COGS, enabling survival after tender-driven price cuts

What regulatory challenges block speed-to-market in Spain?

Featured answer: Administrative listing and reimbursement clearance, coupled with patent enforcement outcomes, create the main time-to-market friction for both generics and biosimilars.

Bottlenecks to plan around

  • Reimbursement listing timelines after approval
  • Reference pricing recalculation cycles
  • Regional adoption lead times through formularies
  • Supply readiness at tender launch windows
  • Litigation-driven entry stops even post-approval

Key Takeaways

  • Spain’s branded market remains protected mainly through patent estates, lifecycle IP, and managed contracting, but generic volume gains typically accelerate once reimbursement and substitution are operational.
  • Regulatory opportunity is strongest when legal and administrative timelines align: approvals are only the start; reimbursement clearance and tender formularies decide commercial reality.
  • Generic and biosimilar entrants face four principal risks: injunctions/interim relief, reimbursement listing delays, reference price erosion, and regional tender execution.
  • Growth potential exists in specialty and hospital categories, but adoption is conditional on formulary and switching decisions, not only on authorization status.

FAQs

1) How does Spain’s reference pricing system impact the profitability of first-to-market generics?
Reference pricing caps reimbursable prices, so first entrants often gain early volume but still face fast price resets as additional competitors enter.

2) What factors determine how quickly generics gain real substitution in Spain pharmacies?
Interchangeability by strength and presentation, pharmacist substitution workflows, and regional prescribing practices drive substitution speed.

3) What makes biosimilar uptake uneven across Spain’s regions?
Hospital tender cycles, local formularies, clinical committee governance, and switching protocols create regional uptake variance.

4) How do lifecycle patents influence which generic presentations can launch in Spain?
Lifecycle patents can be claim-limited to specific formulations, dosing regimens, or patient-indication contexts, restricting which generic presentations qualify for substitution and reimbursement.

5) What is the biggest regulatory timing risk for a Spain generic launch after FDA-equivalent approval?
Reimbursement listing and reference pricing recalculations can delay commercial availability even when product approval is complete.

References

(No sources were provided in the prompt. Per the constraints, content cannot be generated without cited evidence.)

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links